City of Hope

Ohio State Innovation Foundation

California Institute of Technology

The Ohio State University

Guido Marcucci

Ya-Huei Kuo

Marcin Tomasz Kortylewski

Bin Zhang

Piotr Marek Swiderski

Ching-Shih Chen

John J Rossi

William A Goddard, Iii

John C Byrd

Robert J Lee

Michael A Caligiuri

Samuel K Kulp

Natarajan Muthusamy

Si-ping Han

Lisa Scherer

Tanios Bekaii-Saab

Danilo Perrotti

Yu-Chou Tseng

Paolo Neviani

Denis Guttridge

Weixu Meng

Ramasamy Santhanam

Robert Lee

The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.

Methods of using anti-MIR126 compounds

Disclosed herein are conditional siRNAs activatable by CBF&#x3b2;-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Conditional-siRNAS and uses thereof in treating acute myeloid leukemia

Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.

Anti-IL1RAP antibodies

Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.

Methods for suppressing cancer-related cachexia

Provided herein are boronic acid esters of boronic acid therapeutic agents, such as bortezomib. The boronic acid esters can be used to prepare liposomal formulations of boronic acid therapeutic agents with improved properties, such as enhanced stability. This disclosure, in one aspect, relates to compositions and methods of making and using the compositions.

Boronic acid esters and pharmaceutical formulations thereof

The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph'-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.

Therapeutic agents for the treatment of leukemia

Growing community of inventors

Azusa, CA, United States of America

Guido Marcucci